Institutional members access full text with Ovid®

Share this article on:

Preexposure prophylaxis: An emerging clinical approach to preventing HIV in high-risk adults

Blackwell, Christopher W. PhD, ARNP, ANP-BC, CNE, AGACNP-BC

doi: 10.1097/01.NPR.0000452976.92052.fa
Feature: HIV

Abstract: The HIV antiretroviral drug emtricitabine/tenofovir disoproxil fumarate (Truvada) was recently approved as preexposure prophylaxis (PrEP) therapy for adults at high risk for sexually acquired HIV infection. This article reviews the data supporting the efficacy of PrEP, and provides other relevant data regarding the implementation of PrEP.

Christopher W. Blackwell is an associate professor and coordinator of Nurse Practitioner Programs at University of Central Florida, College of Nursing, Orlando, Fla.

The author have disclosed that they have no financial relationships related to this article.

Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved.